892 related articles for article (PubMed ID: 28190531)
1. Cutaneous adverse effects of the immune checkpoint inhibitors.
Collins LK; Chapman MS; Carter JB; Samie FH
Curr Probl Cancer; 2017; 41(2):125-128. PubMed ID: 28190531
[TBL] [Abstract][Full Text] [Related]
2. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance.
Bhardwaj M; Chiu MN; Pilkhwal Sah S
Cutan Ocul Toxicol; 2022 Mar; 41(1):73-90. PubMed ID: 35107396
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Summarized Overview.
Plachouri KM; Vryzaki E; Georgiou S
Curr Drug Saf; 2019; 14(1):14-20. PubMed ID: 30058498
[TBL] [Abstract][Full Text] [Related]
4. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
Sibaud V
Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous Complications of Targeted Melanoma Therapy.
de Golian E; Kwong BY; Swetter SM; Pugliese SB
Curr Treat Options Oncol; 2016 Nov; 17(11):57. PubMed ID: 27645330
[TBL] [Abstract][Full Text] [Related]
6. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
Weber JS; Postow M; Lao CD; Schadendorf D
Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text].
Muntyanu A; Netchiporouk E; Gerstein W; Gniadecki R; Litvinov IV
J Cutan Med Surg; 2021; 25(1):59-76. PubMed ID: 32746624
[TBL] [Abstract][Full Text] [Related]
8. Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies.
Sibaud V; Meyer N; Lamant L; Vigarios E; Mazieres J; Delord JP
Curr Opin Oncol; 2016 Jul; 28(4):254-63. PubMed ID: 27136138
[TBL] [Abstract][Full Text] [Related]
9. Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue.
Varricchi G; Marone G; Mercurio V; Galdiero MR; Bonaduce D; Tocchetti CG
Curr Med Chem; 2018; 25(11):1327-1339. PubMed ID: 28403786
[TBL] [Abstract][Full Text] [Related]
10. Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis.
Abdel-Rahman O; ElHalawani H; Fouad M
Future Oncol; 2015; 11(17):2471-84. PubMed ID: 26274495
[TBL] [Abstract][Full Text] [Related]
11. Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma.
Kähler KC; Hassel JC; Heinzerling L; Loquai C; Mössner R; Ugurel S; Zimmer L; Gutzmer R;
J Dtsch Dermatol Ges; 2016 Jul; 14(7):662-81. PubMed ID: 27373241
[TBL] [Abstract][Full Text] [Related]
12. Managing immune checkpoint-blocking antibody side effects.
Postow MA
Am Soc Clin Oncol Educ Book; 2015; ():76-83. PubMed ID: 25993145
[TBL] [Abstract][Full Text] [Related]
13. Safety of pembrolizumab for the treatment of melanoma.
Martin-Liberal J; Kordbacheh T; Larkin J
Expert Opin Drug Saf; 2015 Jun; 14(6):957-64. PubMed ID: 25927979
[TBL] [Abstract][Full Text] [Related]
14. Management of toxicities of immune checkpoint inhibitors.
Spain L; Diem S; Larkin J
Cancer Treat Rev; 2016 Mar; 44():51-60. PubMed ID: 26874776
[TBL] [Abstract][Full Text] [Related]
15. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor.
Belum VR; Benhuri B; Postow MA; Hellmann MD; Lesokhin AM; Segal NH; Motzer RJ; Wu S; Busam KJ; Wolchok JD; Lacouture ME
Eur J Cancer; 2016 Jun; 60():12-25. PubMed ID: 27043866
[TBL] [Abstract][Full Text] [Related]
16. Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patients.
Tetzlaff MT; Jazaeri AA; Torres-Cabala CA; Korivi BR; Landon GA; Nagarajan P; Choksi A; Chen L; Uemura M; Aung PP; Diab A; Sharma P; Davies MA; Amaria R; Prieto VG; Curry JL
J Cutan Pathol; 2017 Dec; 44(12):1080-1086. PubMed ID: 28901560
[TBL] [Abstract][Full Text] [Related]
17. [Management of Toxicities of Immune Checkpoint Inhibitors].
Horio Y
Gan To Kagaku Ryoho; 2017 Mar; 44(3):185-190. PubMed ID: 28292987
[TBL] [Abstract][Full Text] [Related]
18. Endocrine side effects induced by immune checkpoint inhibitors.
Corsello SM; Barnabei A; Marchetti P; De Vecchis L; Salvatori R; Torino F
J Clin Endocrinol Metab; 2013 Apr; 98(4):1361-75. PubMed ID: 23471977
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic Cutaneous Adverse Drug Reactions during Anti-PD-1 Therapy.
Goldinger SM; Stieger P; Meier B; Micaletto S; Contassot E; French LE; Dummer R
Clin Cancer Res; 2016 Aug; 22(16):4023-9. PubMed ID: 26957557
[TBL] [Abstract][Full Text] [Related]
20. Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma.
Reddy SB; Possick JD; Kluger HM; Galan A; Han D
J Immunother; 2017 Oct; 40(8):307-311. PubMed ID: 28737620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]